Get the Stockscreener App
425.28
1.42%
5.90
After Hours:
425.28
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $425.28, with a volume of 2.56M.
It is up +1.42% in the last 24 hours and up +16.12% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$419.38
Open:
$421.64
24h Volume:
2.56M
Relative Volume:
0.97
Market Cap:
$230.08B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
29.58
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.66%
1M Performance:
+16.12%
6M Performance:
+12.01%
1Y Performance:
+45.35%
1-Day Range:
$420.72
$427.39
1-Week Range:
$409.00
$427.39
52-Week Range:
$269.77
$427.39
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
425.28 | 226.88B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,226.66 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.13 | 632.29B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
258.94 | 442.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.18 | 335.46B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.59 | 288.85B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
The Bull Case For Amgen (AMGN) Could Change Following Raised 2026 Earnings Guidance And Q2 BeatLearn Why - simplywall.st
Cantor Fitzgerald raises Amgen stock price target on core portfolio strength - Investing.com India
Amgen (NASDAQ:AMGN) Reaches New 1-Year High on Analyst Upgrade - MarketBeat
Amgen stock hits all-time high at 422.49 USD By Investing.com - Investing.com India
Resilient Amgen stock trades above $419 as earnings beat and 2026 guidance support momentum - AD HOC NEWS
Amgen (NASDAQ:AMGN) Given New $352.00 Price Target at Mizuho - MarketBeat
Cantor Fitzgerald Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
AMGN Maintains by Cantor Fitzgerald -- Price Target Raised to $4 - GuruFocus
Wilkinson Global Asset Management LLC Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Russell Investments Group Ltd. Sells 37,910 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Kinsale Capital Group Inc. - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Purchases 5,903 Shares of Amgen Inc. $AMGN - MarketBeat
Kelleher Financial Advisors Buys 2,580 Shares of Amgen Inc. $AMGN - MarketBeat
Global Retirement Partners LLC Takes $8.88 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds above $415 as Q2 2026 growth and guidance support valuation - AD HOC NEWS
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Mizuho Securities Adjusts Amgen Price Target to $352 From $303 - marketscreener.com
Amgen stock holds firm after Q2 sales raised the bar - AD HOC NEWS
AMGN DCF Analysis: Intrinsic Value $296 vs Price $415 - GuruFocus
KBC Group NV Acquires 130,497 Shares of Amgen Inc. $AMGN - MarketBeat
HighTower Advisors LLC Has $295.58 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Lessened by Fifth Third Bancorp - MarketBeat
Amgen Inc. $AMGN Shares Bought by Bridgewater Advisors Inc. - MarketBeat
111 Capital Has $1.40 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as analyst lifts price target on obesity drug focus - AD HOC NEWS
Should Income Investors Look At Amgen Inc. (NASDAQ:AMGN) Before Its Ex-Dividend? - simplywall.st
Amgen Inc. $AMGN Shares Sold by Strive Financial Group LLC - MarketBeat
Principal Financial Group Inc. Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co. - MarketBeat
Todd Asset Management LLC Sells 19,948 Shares of Amgen Inc. $AMGN - MarketBeat
Commonwealth Retirement Investments LLC Decreases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
TCW Group Inc. Has $10.27 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Hussman Strategic Advisors Inc. Has $3.04 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Oppenheimer & Co. Inc. - MarketBeat
Vontobel Holding Ltd. Acquires 4,637 Shares of Amgen Inc. $AMGN - MarketBeat
Elyxium Wealth LLC Has $5.16 Million Holdings in Amgen Inc. $AMGN - MarketBeat
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - Currently.com
Garabedian on Biotech's Post-Deal 'Shoes That Drop': Seven Vykat XR Deaths and Amgen's Tavneos Pull - finance.biggo.com
AMGN Maintained by Barclays -- Price Target Raised to $380 - GuruFocus
Amgen stock holds near 52-week high after earnings beat and insider sale - ad-hoc-news.de
Amgen (AMGN) Stock Looks Below Fair Value As Caution Lingers - simplywall.st
Amgen stock holds above $417 as Q2 2026 beats drive higher guidance - AD HOC NEWS
Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells $521,370.36 in Stock - MarketBeat
Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells $825,140.00 in Stock - MarketBeat
Pharma Company Amgen Joins MrBeast For Pediatric Cancer Dream Team 08/13/2026 - MediaPost
Amgen SVP Rachna Khosla sells $1.35m of stock - Investing.com
Amgen SVP Rachna Khosla sells $1.35m of stock By Investing.com - Investing.com India
Amgen (AMGN) insider Rachna Khosla files to sell 516,775 shares - Stock Titan
Amgen stock holds above $415 as strong Q2 2026 results lift guidance - AD HOC NEWS
Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating - marketscreener.com
Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating - marketscreener.com
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
2.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):